Cargando…

Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy

This analysis aims to describe the outcomes of two nonambulatory patients with Duchenne muscular dystrophy (DMD) who participated in two clinical studies. The two consecutive trials of eteplirsen (studies 201 and 202) were conducted in patients with DMD (N = 12) and confirmed genetic mutations amena...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alfano, Lindsay N., Charleston, Jay S., Connolly, Anne M., Cripe, Linda, Donoghue, Cas, Dracker, Robert, Dworzak, Johannes, Eliopoulos, Helen, Frank, Diane E., Lewis, Sarah, Lucas, Karin, Lynch, Jessie, Milici, A. J., Flynt, Amy, Naughton, Emily, Rodino-Klapac, Louise R., Sahenk, Zarife, Schnell, Frederick J., Young, G. David, Mendell, Jerry R., Lowes, Linda P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617421/ https://www.ncbi.nlm.nih.gov/pubmed/31261494 http://dx.doi.org/10.1097/MD.0000000000015858

Ejemplares similares

Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
por: Mendell, Jerry R., et al.
Publicado: (2016)

Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls
por: Mendell, Jerry R., et al.
Publicado: (2021)

Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy
por: Khan, Navid, et al.
Publicado: (2019)

Long-Term Pulmonary Function in Duchenne Muscular Dystrophy: Comparison of Eteplirsen-Treated Patients to Natural History
por: Kinane, T. Bernard, et al.
Publicado: (2018)

Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial
por: Mendell, Jerry R., et al.
Publicado: (2020)

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017)

Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy
por: Al-Zaidy, Samiah A., et al.
Publicado: (2015)

Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy
por: Mendell, Jerry R., et al.
Publicado: (2023)

Eteplirsen Use in a Boy with Duchenne Muscular Dystrophy and Sickle Cell Anemia
por: Aiello, Gregory M., et al.
Publicado: (2022)

Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial
por: McDonald, Craig M., et al.
Publicado: (2021)

Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA
por: Iff, Joel, et al.
Publicado: (2023)

AAV1.NT-3 Gene Therapy for Charcot–Marie–Tooth Neuropathy
por: Sahenk, Zarife, et al.
Publicado: (2014)

Expression and function of four AAV-based constructs for dystrophin restoration in the mdx mouse model of Duchenne muscular dystrophy
por: Potter, Rachael A., et al.
Publicado: (2023)

Efficacy of stem cell therapy in ambulatory and nonambulatory children with Duchenne muscular dystrophy – Phase I–II
por: Dai, Alper, et al.
Publicado: (2018)

Assessment of rAAVrh.74.MHCK7.micro-dystrophin Gene Therapy Using Magnetic Resonance Imaging in Children With Duchenne Muscular Dystrophy
por: Willcocks, Rebecca J., et al.
Publicado: (2021)

Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States
por: Klimchak, Alexa C., et al.
Publicado: (2023)

A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy
por: Rodino-Klapac, Louise R, et al.
Publicado: (2007)

Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy
por: Potter, Rachael A., et al.
Publicado: (2021)

Persistent Expression of FLAG-tagged Micro dystrophin in Nonhuman Primates Following Intramuscular and Vascular Delivery
por: Rodino-Klapac, Louise R, et al.
Publicado: (2009)

Glucocorticoid Therapy for Duchenne Cardiomyopathy: A Hobson's Choice?
por: Raman, Subha V., et al.
Publicado: (2015)

AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models
por: Sondergaard, Patricia C, et al.
Publicado: (2015)

Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD
por: Wallace, Lindsay M., et al.
Publicado: (2017)

Health Parameters in Standing and Nonstanding Nonambulatory Adults With Cerebral Palsy
por: Murphy, Kevin P., et al.
Publicado: (2021)

Development of Duchenne Video Assessment scorecards to evaluate ease of movement among those with Duchenne muscular dystrophy
por: Contesse, Marielle G., et al.
Publicado: (2022)

MicroRNA Based Treatment of Cardiomyopathy: Not all Dystrophies are Created Equal
por: Rodino‐Klapac, Louise R.
Publicado: (2013)

A Multidisciplinary Approach to the Nonambulatory Bariatric Patient With Bilateral Knee Osteoarthritis
por: Domingue, Grayson, et al.
Publicado: (2023)

A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment
por: Mitelman, Olga, et al.
Publicado: (2022)

Reliability and construct validity of the Duchenne Video Assessment
por: Contesse, Marielle G., et al.
Publicado: (2021)

Left ventricular noncompaction in Duchenne muscular dystrophy
por: Statile, Christopher J, et al.
Publicado: (2013)

Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)
por: Finkel, Richard S., et al.
Publicado: (2023)

Hip Pain in Nonambulatory Children with Type-I or II Spinal Muscular Atrophy
por: Hanna, Rewais B., et al.
Publicado: (2022)

Surgical Technique for Targeted Muscle Reinnervation in Knee Disarticulation Amputation for Nonambulatory Patients
por: Felder, John M., et al.
Publicado: (2023)

Systemic delivery of AAVrh74.tMCK.hCAPN3 rescues the phenotype in a mouse model for LGMD2A/R1
por: Sahenk, Zarife, et al.
Publicado: (2021)

Emerging therapeutic options for sporadic inclusion body myositis
por: Alfano, Lindsay N, et al.
Publicado: (2015)

S100β Levels in CSF of Nonambulatory Dogs with Intervertebral Disk Disease Treated with Electroacupuncture
por: Murata Hayashi, Ayne, et al.
Publicado: (2013)

A novel p.T139M mutation in HSPB1 highlighting the phenotypic spectrum in a family
por: Amornvit, Jakkrit, et al.
Publicado: (2017)

Effect of pulmonary function on right heart function in Duchenne muscular dystrophy patients
por: Subramanian, Sharath, et al.
Publicado: (2015)

Accelerometry: A Feasible Method to Quantify Physical Activity in Ambulatory and Nonambulatory Adolescents with Cerebral Palsy
por: Gorter, Jan Willem, et al.
Publicado: (2012)

Variability in Postoperative Immobilization and Rehabilitation Following Reconstructive Hip Surgery in Nonambulatory Children With Cerebral Palsy
por: Miller, Stacey D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lp5c3t83p6605ojh24596oqp74